<DOC>
	<DOCNO>NCT00005093</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether gemcitabine plus CI-994 effective gemcitabine alone non-small cell lung cancer . PURPOSE : Randomized phase III trial compare effectiveness gemcitabine without CI-994 treat patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine With Without CI-994 Treating Patients With Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy safety gemcitabine without CI-994 patient advance non-small cell lung cancer . OUTLINE : This randomize , double blind , placebo control , multicenter study . Patients stratify accord performance status randomize one two treatment arm . Arm I : Patients receive CI-994 orally day 1-21 gemcitabine IV 30 minute day 1 , 8 , 15 . Arm II : Patients receive placebo capsule orally day 1-21 gemcitabine arm I . Treatment repeat every 28 day long medically appropriate ( absence disease progression unacceptable toxicity ) . PROJECTED ACCRUAL : A total 176 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm recurrent , locally advanced , metastatic , unresectable nonsmall cell lung cancer Failed relapse one prior platinum contain regimen ( cisplatin carboplatin ) first line therapy Prior brain metastasis allow resection and/or radiotherapy complete , worsen CNS symptom , least 1 month since prior corticosteroid PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Greater 12 week Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN ( great 5 time ULN patient liver metastasis ) Renal : Creatinine clearance least 50 mL/min Other : Able swallow intact study capsule No active infection No life threaten illness ( tumor ) No prior malignancy within past 5 year except well control nonmelanomatous skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No one prior regimen chemotherapy No prior gemcitabine No prior CI994 At least 4 week since prior maintenance consolidation therapy ( e.g. , matrix metalloprotein inhibitor ) Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy primary site Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>